Login / Signup

Inhibition of α-Glucosidase, Acetylcholinesterase, and Nitric Oxide Production by Phytochemicals Isolated from Millettia speciosa -In Vitro and Molecular Docking Studies.

Nguyen Ngoc TuanHuong Nguyen ThiChau Le Thi MyTang Xuan HaiHieu Tran TrungAnh Nguyen Thi KimThanh Nguyen TanVan Tan LeCuong Quoc NguyenQuang De TranPing-Chung KuoQuang Le DangTran Dinh Thang
Published in: Plants (Basel, Switzerland) (2022)
The phytochemical constituents from the roots of Millettia speciosa were investigated by chromatographic isolation, and their chemical structures were characterized using the MS and NMR spectroscopic methods. A total of 10 compounds, including six triterpenoids, two flavonoids, and two phenolic compounds, were identified from the roots of M. speciosa . Out of the isolated compounds, eight showed inhibitory effects on NO production in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, with IC 50 values ranging from 43.9 to 449.5 µg/mL. Ursane-type triterpenes significantly suppressed NO production compared to the remaining compounds. In addition, these compounds also exhibited remarkable inhibitory effects on α-glucosidase. Among the tested compounds, 4 , 5 , and 10 exhibited excellent α-glucosidase inhibition, with IC 50 values ranging from 1.1 to 2.2 µg/mL. Almost all of the test compounds showed little or no acetylcholinesterase inhibition, except for 5, which showed moderate anti-acetylcholinesterase activity in vitro. The molecular docking study of α-glucosidase inhibition by 3 - 5 and 10 was conducted to observe the interactions of these molecules with the enzyme. Compounds 4 , 5 , and 10 exhibited a better binding affinity toward the targeted receptor and the H-bond interactions located at the entrance of the enzyme active site pocket in comparison to those of 3 and the positive control acarbose. Our findings evidence the pharmacological potential of this species and suggest that the phytochemicals derived from the roots of M. speciosa may be promising lead molecules for further studies on the development of anti-inflammatory and anti-diabetes drugs.
Keyphrases